Salix, Lupin ink technology deal for Xifaxan
RALEIGH, N.C. — Indian drug maker Lupin and U.S. drug maker Salix Pharmaceuticals announced Wednesday a licensing deal for technology related to a drug for traveler’s diarrhea.
Under the deal, Salix will receive exclusive worldwide rights for Xifaxan (rifaximin) drug technology developed by Lupin and jointly by both companies in all countries except India.
Salix is required to pay Lupin $10 million upfront, as well as potential payments related to regulatory milestones.
BioScrip receives URAC accreditation
ELMSFORD, N.Y. — Washington-based healthcare accrediting organization URAC has awarded specialty pharmacy and mail-service pharmacy accreditation to BioScrip, the specialty pharmacy provider said Wednesday.
“BioScrip is very pleased to have been awarded full accreditation for both specialty pharmacy and mail-serve pharmacy from URAC,” BioScrip president and CEO Richard Smith said. “Going through the process challenged us to find better ways to serve our customers, and it is a constant reminder that our first responsibility is to the patient and the quality of clinical serve we provide.”
The accreditation required BioScrip to participate in a complex application process that included comprehensive review of its customer service and clinical pharmacy processes against a combined 146 quality standards by expert analysts, the company said.
Shire files lawsuit against Watson over Adderall XR
DUBLIN — British drug maker Shire has filed suit against Watson Pharmaceuticals and subsidiaries, alleging patent infringement in a case concerning a drug used to treat attention deficit hyperactivity disorder.
Shire announced Wednesday that it had filed the suit in the U.S. District Court for the Southern District of New York against Watson and several subsidiaries over their attempt to market a generic version of Adderall XR (amphetamine, dextroamphetamine mixed salts) and breach of contract.
The suit alleges that Watson infringed on three Shire patents and breached a settlement and licensing agreement concerning the drug that the companies reached in November 2007 by filing for approval of a generic version of Adderall XR with the Food and Drug Administration.